|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GSTM2 |
Gene summary for GSTM2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GSTM2 | Gene ID | 2946 |
| Gene name | glutathione S-transferase mu 2 | |
| Gene Alias | GST4 | |
| Cytomap | 1p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0001676 | UniProtAcc | P28161 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2946 | GSTM2 | LZE2T | Human | Esophagus | ESCC | 3.55e-16 | 1.41e+00 | 0.082 |
| 2946 | GSTM2 | LZE4T | Human | Esophagus | ESCC | 1.41e-45 | 1.78e+00 | 0.0811 |
| 2946 | GSTM2 | LZE7T | Human | Esophagus | ESCC | 1.56e-14 | 9.34e-01 | 0.0667 |
| 2946 | GSTM2 | LZE20T | Human | Esophagus | ESCC | 1.30e-10 | 3.97e-01 | 0.0662 |
| 2946 | GSTM2 | LZE21D1 | Human | Esophagus | HGIN | 1.52e-08 | 8.69e-01 | 0.0632 |
| 2946 | GSTM2 | LZE22D1 | Human | Esophagus | HGIN | 4.30e-07 | 3.41e-01 | 0.0595 |
| 2946 | GSTM2 | LZE22T | Human | Esophagus | ESCC | 1.57e-03 | 3.61e-01 | 0.068 |
| 2946 | GSTM2 | LZE24T | Human | Esophagus | ESCC | 1.09e-06 | 2.24e-01 | 0.0596 |
| 2946 | GSTM2 | LZE6T | Human | Esophagus | ESCC | 5.35e-04 | 1.86e-01 | 0.0845 |
| 2946 | GSTM2 | P1T-E | Human | Esophagus | ESCC | 2.65e-12 | 4.45e-01 | 0.0875 |
| 2946 | GSTM2 | P2T-E | Human | Esophagus | ESCC | 1.59e-52 | 9.25e-01 | 0.1177 |
| 2946 | GSTM2 | P4T-E | Human | Esophagus | ESCC | 4.30e-23 | 4.74e-01 | 0.1323 |
| 2946 | GSTM2 | P5T-E | Human | Esophagus | ESCC | 4.31e-06 | 1.51e-01 | 0.1327 |
| 2946 | GSTM2 | P8T-E | Human | Esophagus | ESCC | 3.60e-13 | 2.11e-01 | 0.0889 |
| 2946 | GSTM2 | P9T-E | Human | Esophagus | ESCC | 3.63e-74 | 1.67e+00 | 0.1131 |
| 2946 | GSTM2 | P10T-E | Human | Esophagus | ESCC | 3.93e-14 | 3.42e-01 | 0.116 |
| 2946 | GSTM2 | P11T-E | Human | Esophagus | ESCC | 3.25e-05 | 2.20e-01 | 0.1426 |
| 2946 | GSTM2 | P12T-E | Human | Esophagus | ESCC | 5.22e-43 | 8.32e-01 | 0.1122 |
| 2946 | GSTM2 | P15T-E | Human | Esophagus | ESCC | 9.51e-20 | 3.89e-01 | 0.1149 |
| 2946 | GSTM2 | P16T-E | Human | Esophagus | ESCC | 2.41e-29 | 4.30e-01 | 0.1153 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005165126 | Esophagus | HGIN | maintenance of location in cell | 53/2587 | 214/18723 | 1.22e-05 | 3.45e-04 | 53 |
| GO:005123520 | Esophagus | HGIN | maintenance of location | 73/2587 | 327/18723 | 1.73e-05 | 4.71e-04 | 73 |
| GO:00067497 | Esophagus | HGIN | glutathione metabolic process | 20/2587 | 64/18723 | 2.63e-04 | 4.58e-03 | 20 |
| GO:199074820 | Esophagus | HGIN | cellular detoxification | 30/2587 | 116/18723 | 4.05e-04 | 6.15e-03 | 30 |
| GO:009723720 | Esophagus | HGIN | cellular response to toxic substance | 30/2587 | 124/18723 | 1.32e-03 | 1.57e-02 | 30 |
| GO:009886920 | Esophagus | HGIN | cellular oxidant detoxification | 25/2587 | 101/18723 | 2.29e-03 | 2.34e-02 | 25 |
| GO:0051235110 | Esophagus | ESCC | maintenance of location | 200/8552 | 327/18723 | 1.01e-08 | 2.02e-07 | 200 |
| GO:00067906 | Esophagus | ESCC | sulfur compound metabolic process | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
| GO:00066318 | Esophagus | ESCC | fatty acid metabolic process | 217/8552 | 390/18723 | 4.21e-05 | 3.39e-04 | 217 |
| GO:000941020 | Esophagus | ESCC | response to xenobiotic stimulus | 253/8552 | 462/18723 | 4.55e-05 | 3.58e-04 | 253 |
| GO:0051651111 | Esophagus | ESCC | maintenance of location in cell | 126/8552 | 214/18723 | 6.57e-05 | 5.00e-04 | 126 |
| GO:00065757 | Esophagus | ESCC | cellular modified amino acid metabolic process | 112/8552 | 188/18723 | 8.31e-05 | 6.06e-04 | 112 |
| GO:000963620 | Esophagus | ESCC | response to toxic substance | 150/8552 | 262/18723 | 1.00e-04 | 7.12e-04 | 150 |
| GO:00463948 | Esophagus | ESCC | carboxylic acid biosynthetic process | 175/8552 | 314/18723 | 1.98e-04 | 1.26e-03 | 175 |
| GO:00160538 | Esophagus | ESCC | organic acid biosynthetic process | 175/8552 | 316/18723 | 3.04e-04 | 1.82e-03 | 175 |
| GO:000674912 | Esophagus | ESCC | glutathione metabolic process | 42/8552 | 64/18723 | 1.01e-03 | 5.12e-03 | 42 |
| GO:1990748110 | Esophagus | ESCC | cellular detoxification | 70/8552 | 116/18723 | 1.02e-03 | 5.17e-03 | 70 |
| GO:0097237110 | Esophagus | ESCC | cellular response to toxic substance | 72/8552 | 124/18723 | 3.65e-03 | 1.49e-02 | 72 |
| GO:0098869110 | Esophagus | ESCC | cellular oxidant detoxification | 60/8552 | 101/18723 | 3.76e-03 | 1.53e-02 | 60 |
| GO:001605321 | Liver | HCC | organic acid biosynthetic process | 200/7958 | 316/18723 | 5.24e-14 | 3.22e-12 | 200 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0520839 | Esophagus | HGIN | Chemical carcinogenesis - reactive oxygen species | 92/1383 | 223/8465 | 2.41e-19 | 9.83e-18 | 7.80e-18 | 92 |
| hsa0541839 | Esophagus | HGIN | Fluid shear stress and atherosclerosis | 42/1383 | 139/8465 | 2.92e-05 | 3.81e-04 | 3.02e-04 | 42 |
| hsa05208115 | Esophagus | HGIN | Chemical carcinogenesis - reactive oxygen species | 92/1383 | 223/8465 | 2.41e-19 | 9.83e-18 | 7.80e-18 | 92 |
| hsa05418115 | Esophagus | HGIN | Fluid shear stress and atherosclerosis | 42/1383 | 139/8465 | 2.92e-05 | 3.81e-04 | 3.02e-04 | 42 |
| hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
| hsa05418211 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
| hsa015247 | Esophagus | ESCC | Platinum drug resistance | 56/4205 | 73/8465 | 1.85e-06 | 1.13e-05 | 5.78e-06 | 56 |
| hsa0048018 | Esophagus | ESCC | Glutathione metabolism | 44/4205 | 57/8465 | 1.81e-05 | 9.03e-05 | 4.63e-05 | 44 |
| hsa0522518 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa05208310 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
| hsa05418310 | Esophagus | ESCC | Fluid shear stress and atherosclerosis | 109/4205 | 139/8465 | 2.00e-12 | 3.72e-11 | 1.90e-11 | 109 |
| hsa0152414 | Esophagus | ESCC | Platinum drug resistance | 56/4205 | 73/8465 | 1.85e-06 | 1.13e-05 | 5.78e-06 | 56 |
| hsa0048019 | Esophagus | ESCC | Glutathione metabolism | 44/4205 | 57/8465 | 1.81e-05 | 9.03e-05 | 4.63e-05 | 44 |
| hsa0522519 | Esophagus | ESCC | Hepatocellular carcinoma | 109/4205 | 168/8465 | 4.27e-05 | 1.88e-04 | 9.64e-05 | 109 |
| hsa0520842 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
| hsa052258 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
| hsa0541842 | Liver | HCC | Fluid shear stress and atherosclerosis | 89/4020 | 139/8465 | 5.58e-05 | 2.88e-04 | 1.60e-04 | 89 |
| hsa009832 | Liver | HCC | Drug metabolism - other enzymes | 54/4020 | 80/8465 | 2.25e-04 | 1.09e-03 | 6.08e-04 | 54 |
| hsa0520852 | Liver | HCC | Chemical carcinogenesis - reactive oxygen species | 167/4020 | 223/8465 | 2.85e-17 | 1.91e-15 | 1.06e-15 | 167 |
| hsa0522511 | Liver | HCC | Hepatocellular carcinoma | 106/4020 | 168/8465 | 2.87e-05 | 1.85e-04 | 1.03e-04 | 106 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GSTM2 | insertion | Frame_Shift_Ins | novel | c.520_521insTAACAAA | p.Cys174LeufsTer18 | p.C174Lfs*18 | P28161 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GSTM2 | insertion | Frame_Shift_Ins | novel | c.521_522insTCTCCAGACAGACCTACATGTCC | p.Asp176GlnfsTer14 | p.D176Qfs*14 | P28161 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| GSTM2 | SNV | Missense_Mutation | c.376N>A | p.Glu126Lys | p.E126K | P28161 | protein_coding | tolerated(0.12) | benign(0.019) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| GSTM2 | SNV | Missense_Mutation | novel | c.397N>A | p.Glu133Lys | p.E133K | P28161 | protein_coding | tolerated(0.47) | benign(0.015) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| GSTM2 | SNV | Missense_Mutation | novel | c.25N>G | p.Asn9Asp | p.N9D | P28161 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GSTM2 | SNV | Missense_Mutation | novel | c.445N>A | p.Leu149Ile | p.L149I | P28161 | protein_coding | deleterious(0) | benign(0.025) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GSTM2 | SNV | Missense_Mutation | novel | c.580A>T | p.Ile194Phe | p.I194F | P28161 | protein_coding | deleterious(0) | possibly_damaging(0.721) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| GSTM2 | SNV | Missense_Mutation | c.389N>G | p.Ala130Gly | p.A130G | P28161 | protein_coding | tolerated(1) | benign(0) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| GSTM2 | SNV | Missense_Mutation | novel | c.75C>A | p.Asp25Glu | p.D25E | P28161 | protein_coding | tolerated(0.39) | benign(0.003) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| GSTM2 | SNV | Missense_Mutation | novel | c.448N>A | p.Gly150Arg | p.G150R | P28161 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AJ-A3NH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |